Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Antimicrobial Revision in Persistent Febrile Neutropenia
NCT05784844Phase 4Withdrawn
- Sponsor
- Wake Forest University Health Sciences
- Start
- Aug 2024
- Primary completion
- Apr 2025
- Modality
- Small Molecules
01
Overview
A Phase 4 trial of meropenem, micafungin in febrile neutropenia (FN), sponsored by Wake Forest University Health Sciences. Planned start Aug 2024; status: withdrawn.
02
Drugs
meropenemmicafungin
03
Conditions
febrile neutropenia (FN)
Beyond the preview
Go deeper on NCT05784844.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05784844.